Literature DB >> 21894013

Success and failure of virus-specific T cell responses in hepatitis C virus infection.

Christoph Neumann-Haefelin1, Robert Thimme.   

Abstract

Hepatitis C virus (HCV) infection is only cleared in a minority of infected individuals, the majority of patients develop chronic infection. Chronic HCV infection potentially leads to liver fibrosis, cirrhosis and finally hepatocellular carcinoma. The host immune response is an important determinant in the outcome of HCV infection. Innate as well as adaptive cellular and humoral immune responses mediate important antiviral actions; however, virus-specific T cell responses appear to be most critical. Indeed, strong and multispecific CD4+ as well as CD8+ T cell responses are required for viral clearance. Interestingly, individuals who express certain HLA alleles (which are important for antigen presentation to CD4+ and CD8+ T cells) have a higher chance to clear the virus. The mechanisms of protection by HLA class I alleles such as HLA-B27 have been characterized recently. In most individuals, however, the HCV-specific immune response fails to clear the virus. Several mechanisms underlying this HCV-specific T cell failure have been identified. These include viral factors such as viral escape mutations and immunological factors such as the expression of inhibitory receptors, which lead to CD8+ T cell dysfunction. An in-depth understanding of the determinants of success or failure of the HCV-specific T cell response is critical for the development of prophylactic as well as therapeutic vaccination regimes against HCV. Here, we will discuss the virological and immunological determinants of HCV clearance and persistence.
Copyright © 2011 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21894013     DOI: 10.1159/000329807

Source DB:  PubMed          Journal:  Dig Dis        ISSN: 0257-2753            Impact factor:   2.404


  9 in total

Review 1.  25 years of interferon-based treatment of chronic hepatitis C: an epoch coming to an end.

Authors:  Markus H Heim
Journal:  Nat Rev Immunol       Date:  2013-06-07       Impact factor: 53.106

2.  Modulation of Immune Cell Subsets by Hepatitis C Virus and Antiviral Therapy in Early Virological Response HCV Genotype 4-Infected Patients with Compensated Liver Disease.

Authors:  Sahar Essa; Raja'a Al-Attiyah; Iqbal Siddique; Widad Al-Nakib
Journal:  Med Princ Pract       Date:  2020-09-23       Impact factor: 1.927

3.  Phenotypic and functional alterations of primary human PBMCs induced by HCV non-enveloped capsid-like particles uptake.

Authors:  Polyxeni P Doumba; Elisavet Serti; Maria Boutsikou; Manousos M Konstadoulakis; Urania Georgopoulou; John Koskinas
Journal:  Cell Mol Life Sci       Date:  2013-05-05       Impact factor: 9.261

4.  T cell receptor variable β gene repertoire in liver and peripheral blood lymphocytes of chronically hepatitis C virus-infected patients with and without mixed cryoglobulinaemia.

Authors:  S Russi; G Lauletta; G Serviddio; S Sansonno; V Conteduca; L Sansonno; V De Re; D Sansonno
Journal:  Clin Exp Immunol       Date:  2013-05       Impact factor: 4.330

Review 5.  Immunity and hepatitis C: a review.

Authors:  Rebecca R Terilli; Andrea L Cox
Journal:  Curr HIV/AIDS Rep       Date:  2013-03       Impact factor: 5.071

6.  Mapping the genomic diversity of HCV subtypes 1a and 1b: Implications of structural and immunological constraints for vaccine and drug development.

Authors:  Lize Cuypers; Guangdi Li; Christoph Neumann-Haefelin; Supinya Piampongsant; Pieter Libin; Kristel Van Laethem; Anne-Mieke Vandamme; Kristof Theys
Journal:  Virus Evol       Date:  2016-09-06

7.  Attenuated antigen-specific T cell responses in cirrhosis are accompanied by elevated serum interleukin-10 levels and down-regulation of HLA-DR on monocytes.

Authors:  Jack Peter; Oliver Frey; Andreas Stallmach; Tony Bruns
Journal:  BMC Gastroenterol       Date:  2013-02-27       Impact factor: 3.067

8.  Increased baseline proinflammatory cytokine production in chronic hepatitis C patients with rapid virological response to peginterferon plus ribavirin.

Authors:  Gabriella Par; Laszlo Szereday; Timea Berki; Laszlo Palinkas; Melinda Halasz; Attila Miseta; Geza Hegedus; Julia Szekeres-Bartho; Aron Vincze; Bela Hunyady; Alajos Par
Journal:  PLoS One       Date:  2013-07-09       Impact factor: 3.240

9.  Clinical Evaluation of Terap C Vaccine in Combined Treatment with Interferon and Ribavirin in Patients with Hepatitis C.

Authors:  Dorta Guridi Zaily; Castellanos Fernandez Marlen; Dueñas-Carrera Santiago; Martínez Donato Gillian; Valenzuela Silva Carmen; Cinza Estevez Zurina; Arús Soler Enrique R; Alvarez-Lajonchere Liz; González Fabián Lisset; Lazo Del Vallín Sacha; Ferrer Bataille Elena
Journal:  Curr Ther Res Clin Exp       Date:  2017-04-27
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.